← Evidence library

BIB_171

Tawbi HA et al. Relatlimab + nivolumab vs nivolumab alone in untreated advanced melanoma (RELATIVITY-047). NEJM 2022;386(1):24–34. PMID 34986285. LAG-3 + PD-1 approval; PFS HR 0.75. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

PMID:34986285

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_171/findings.md (research corpus). This page is a short context summary — not individualised medical advice.